Evogene Ltd.
EVGN
$1.06
$0.010.47%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 5.65M | 4.61M | 6.64M | 5.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 5.65M | 4.61M | 6.64M | 5.72M |
| Cost of Revenue | -- | 2.44M | 2.09M | 1.56M | 1.66M |
| Gross Profit | -- | 3.20M | 2.53M | 5.08M | 4.06M |
| SG&A Expenses | -- | 9.36M | 9.61M | 8.67M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 500.00K | -- | -- | -3.50M |
| Total Operating Expenses | -- | 25.54M | 27.06M | 27.35M | 28.38M |
| Operating Income | -- | -19.89M | -22.45M | -20.72M | -22.66M |
| Income Before Tax | -- | -15.80M | -23.14M | -20.26M | -22.42M |
| Income Tax Expenses | -- | 8.00K | -3.00K | -9.00K | 16.00K |
| Earnings from Continuing Operations | -- | -15.81 | -23.14 | -20.25 | -22.44 |
| Earnings from Discontinued Operations | -- | -1.47M | -1.47M | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 1.57M | 1.87M | 1.16M | 2.16M |
| Net Income | -- | -16.49M | -23.51M | -19.87M | -20.28M |
| EBIT | -- | -19.89M | -22.45M | -20.72M | -22.66M |
| EBITDA | -- | -18.36M | -20.85M | -18.66M | -20.07M |
| EPS Basic | -- | -3.08 | -4.44 | -3.94 | -4.74 |
| Normalized Basic EPS | -- | 0.02 | -0.74 | -1.26 | -1.75 |
| EPS Diluted | -- | -3.08 | -4.44 | -3.94 | -4.74 |
| Normalized Diluted EPS | -- | 0.02 | -0.74 | -1.26 | -1.75 |
| Average Basic Shares Outstanding | -- | 22.77M | 21.04M | 20.12M | 17.33M |
| Average Diluted Shares Outstanding | -- | 22.77M | 21.04M | 20.12M | 17.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |